Showing results (1981-1990 of 2,232) with videos related to
Sort By:
Pageof 224
Therapeutic Advances in Medical Oncology|April 28, 2023
Circulating tumor cells dynamics during chemotherapy predict survival and response in advanced non-small-cell lung cancer patientsZhen Wang, Xu-Chao Zhang, Wei-Neng Feng, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 3, 2017
Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker AnalysesTony S K Mok, Sang-We Kim, Yi-Long Wu, et al.Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|April 16, 2013
Initiation of apoptosis, cell cycle arrest and autophagy of esophageal cancer cells by dihydroartemisininXiao-Xue Du, Yan-Jing Li, Chun-Long Wu, et al.Cancer Cell|June 21, 2024
Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III non-small-cell lung cancer: A proof-of-concept, phase 2 trialQing Zhou, Yi Pan, Xuening Yang, et al.Lung Cancer (Amsterdam, Netherlands)|November 16, 2018
Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancerSi-Yang Liu, Zhong-Yi Dong, Si-Pei Wu, et al.The Lancet. Oncology|September 30, 2017
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trialYi-Long Wu, Ying Cheng, Xiangdong Zhou, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2009
Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancerTony S K Mok, Yi-Long Wu, Chong-Jen Yu, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 9, 2016
Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment RegimensLuis Paz-Ares, Vera Hirsh, Li Zhang, et al.Frontiers in Oncology|December 28, 2020
Complex ALK Fusions Are Associated With Better Prognosis in Advanced Non-Small Cell Lung CancerJin Kang, Xu-Chao Zhang, Hua-Jun Chen, et al.Nature Communications|April 18, 2019
Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patientsXu-Chao Zhang, Jun Wang, Guo-Guang Shao, et al.Pageof 224